Overview

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized open label dose finding study to evaluate the efficacy and safety of F-627 on women with Stage I-IV breast cancer receiving chemotherapy treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Generon (Shanghai) Corporation Ltd.